Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 11, 2023
Clinical trials for Co-Dx PCR Home™ platform remain on track; Solid cash position and grant funding support long-term strategy SALT LAKE CITY, May 11, 2023 /PRNewswire/ -- Co-Diagnostics, Inc....
-
May 9, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
May 5, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first...
-
Apr 26, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Apr 13, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Mar 21, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Mar 17, 2023Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22
Chair of Company's SAB, Dr. Carl Wittwer, to present on at-home PCR testing SALT LAKE CITY, March 17, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a...
-
Mar 16, 2023
Full-year Results Impacted by Lower Demand for COVID-19 Testing Announced Initiation of Clinical Evaluations for Co-Dx PCR Home™ Platform SALT LAKE CITY, March 16, 2023 /PRNewswire/ --...
-
Mar 9, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth...
-
Mar 2, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Feb 28, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
-
Feb 22, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced...
-
Feb 2, 2023
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
-
Jan 24, 2023
Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33 million sold worldwide; Company also...
-
Jan 5, 2023
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Nov 30, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Nov 14, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Nov 10, 2022
Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ --...
-
Nov 3, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Nov 1, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Oct 27, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third...
-
Oct 26, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Oct 19, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Sep 14, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Sep 12, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Aug 31, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or Co-Dx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Aug 22, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
-
Aug 11, 2022
Second quarter results impacted by volume declines; Further progress on the development of the Co-Dx PCR Home platform SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:...
-
Aug 2, 2022
In the news release, CO-DIAGNOSTICS, INC. ANNOUNCES FIRST QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST, issued 02-Aug-2022 by Co-Diagnostics over PR Newswire, we are advised by the company that...
-
Jul 27, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jul 26, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jul 20, 2022
The Company will also be providing an update to its distributors and other customers on July 26 at 11 am CT. SALT LAKE CITY, July 20, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the...
-
Jul 11, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
Jun 28, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jun 15, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Jun 9, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
May 26, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
May 19, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...
-
May 12, 2022
Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular...
-
May 3, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Apr 28, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first...
-
Apr 22, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Apr 19, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
-
Mar 24, 2022
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY, March 24, 2022 /PRNewswire/ -- Co-Diagnostics, Inc....
-
Mar 22, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
-
Mar 17, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce...
-
Mar 15, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its...
-
Mar 14, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth...
-
Feb 17, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
-
Feb 10, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...